These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26060141)

  • 1. Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
    Iannino-Renz R; Mager D
    Appl Nurs Res; 2015 Aug; 28(3):251-3. PubMed ID: 26060141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
    Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
    Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
    Bacconi L; Gressier F
    Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
    Mostafa T
    Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
    van Landingham SW; Singman EL
    Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current role of sildenafil in the management of erectile dysfunction].
    Akhvlediani ND; Matyukhov IP
    Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE-5 inhibitors: clinical points.
    Doumas M; Lazaridis A; Katsiki N; Athyros V
    Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PDE-5 inhibitors: patients preferences].
    Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
    Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
    Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
    Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dosage forms of sildenafil in the management of erectile dysfunction].
    Grigoryan VA; Gazimiev MA; Demidko YL; Baiduvaliev AM
    Urologiia; 2018 Mar; (1):159-162. PubMed ID: 29634153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
    Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
    Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
    Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
    JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
    Cormier J; Theriot M
    Undersea Hyperb Med; 2016; 43(4):463-465. PubMed ID: 28763176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Erectile dysfunction, PDE5A inhibitors and melanoma].
    Schmutz JL
    Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
    Porst H; Hell-Momeni K; Büttner H
    Expert Opin Pharmacother; 2012 Jul; 13(10):1481-94. PubMed ID: 22725705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
    Houslay MD
    Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Phosphodiasterase 5-Inhibitors (PDE-5i) for Erectile Dysfunction (ED): A Therapeutic Challenge For Psychiatrists.
    Koon CS; Sidi H; Kumar J; Xi OW; Das S; Hatta MH; Alfonso C
    Curr Drug Targets; 2018; 19(12):1366-1377. PubMed ID: 28215172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.